GLPG0974 is a potent and selective FFA2 (also called GPR43) antagonist with IC50 of 9 nM. GLPG0974 inhibits acetate-induced neutrophil migration strongly in vitro and demonstrated ability to inhibit a neutrophil-based pharmacodynamic (PD) marker, CD11b activation-specific epitope [AE], in a human whole blood assay.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Meng Li, et al. Front Pharmacol. The Anti-inflammatory Effects of Short Chain Fatty Acids on Lipopolysaccharide- or Tumor Necrosis Factor α-Stimulated Endothelial Cells via Activation of GPR41/43 and Inhibition of HDACs
|Related FAS Products|
TVB-3664 is a FASN inhibitor which significantly reduces tubulin palmitoylation and mRNA expression.
Triheptanoin (IND106011; UX007) is a fatty acid metabolic modulator.
Rimiducid (AP1903) is a lipid-permeable tacrolimus analogue acts by cross-linking the FKBP domains. *The compound is unstable in solutions, freshly prepared is recommended
Fatostatin A is a cell permeable inhibitor of SREBP activation, it inhibits cancer cell proliferation by affecting mitotic microtubule spindle assembly and cell division.
C75 trans is an enantiomer of C75, which is a synthetic fatty-acid synthase (FASN) inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.